Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cracking the China conundrum & "Robo-reps"

This article was originally published in Scrip

Executive Summary

Think China, think Europe and deploy a mix of traditional and new digital channels to drive growth in the world's second-largest healthcare market. And yes, tele-video detailing/remote detailing, or a "Robo-rep" approach if you will, hold significant scope in China to provide an effective method to reach healthcare professionals directly, with a clear high return on investment.

You may also be interested in...



Ransomware Attacks: The State Of Play As Indian Firms Mount Defense

Pharma continues to be targeted by cyber criminals – the latest being India’s top-ranked company, Sun Pharma. Experts highlight some of the key vulnerabilities and why firms need to prioritize cyber resilience.

What Pharma CEOs, PEs Want To Move The Innovation Needle In India

Leaders of biopharma and private equity firms at a recent conference sought a robust domestic market and reimbursement mechanism to propel the innovation ecosystem in India, drawing parallels with the framework that aided China's ascent in the R&D value chain. Alongside, regulatory reform is also pivotal, they stressed.

Backed By Big Names, Etherna Hopes To Disrupt mRNA Space

Belgian mRNA technologies firm Etherna, which is backed by high profile investors including former Bayer CEO Marijn Dekkers and Moderna co-founder Kenneth Chien, has reoriented its business model. Interim CEO Bernard Sagaert tells In Vivo how the firm hopes to deliver superior products for partners in the rapidly expanding RNA space.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC025718

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel